KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.
about
Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancerHuman adipose tissue-derived stromal/stem cells promote migration and early metastasis of triple negative breast cancer xenograftsA phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.Circadian and melatonin disruption by exposure to light at night drives intrinsic resistance to tamoxifen therapy in breast cancer.Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancerSmall molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges.Melatonin: an inhibitor of breast cancer.Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancerPeptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenograftsIdentification of potential inhibitors based on compound proposal contest: Tyrosine-protein kinase Yes as a target.Circadian gating of epithelial-to-mesenchymal transition in breast cancer cells via melatonin-regulation of GSK3β.Targeting SRC and tubulin in mucinous ovarian carcinoma.Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1.Effects of 17β-estradiol and tamoxifen on gastric cancer cell proliferation and apoptosis and ER-α36 expressionInvading one step at a time: the role of invadopodia in tumor metastasis.Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.The regulatory roles of phosphatases in cancer.Src Family Kinases in Brain Edema After Acute Brain Injury.Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ERα-negative Breast Cancers to Tamoxifen through ERα Reexpression.An ion-current-based, comprehensive and reproducible proteomic strategy for comparative characterization of the cellular responses to novel anti-cancer agents in a prostate cell model.Targeting Src attenuates peritoneal fibrosis and inhibits the epithelial to mesenchymal transition.Human Adipose Tissue-Derived Stromal/Stem Cells Promote Migration and Early Metastasis of Head and Neck Cancer Xenografts.Antitumor Effect of KX-01 through Inhibiting Src Family Kinases and Mitosis.Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update.Managing postmenopausal women with hormone receptor-positive advanced breast cancer who progress on endocrine therapies with inhibitors of the PI3K pathway.
P2860
Q26825584-771E4493-28C0-41C9-BA3A-21881FC1211CQ27320297-A3851C7E-317B-415A-9D49-B7268FDA53D6Q33405571-B64DFF2A-8C27-4015-A67E-C9B3955ACC6BQ33992390-824ED7CF-E284-4445-B604-402FF41CF57AQ34211720-13A6CADB-91A2-4618-9EA4-3B337CE2CDCBQ34992505-E2357FFA-8348-488E-B583-198DF0F9FF90Q35689110-EC45295F-7D3E-45CA-9210-7216F66326B9Q36067934-E850827F-A952-48CF-B7BB-1D029ECC129AQ36290579-29834804-36E3-41F1-8668-64162B212F99Q36320975-C5749CD1-7BDA-4234-8BD9-586777CA59E6Q36367178-166E532B-0C3B-47A0-BBA2-F751F40813ECQ37366157-66D90B5A-FF08-4E07-A9A8-3E8F01D9731BQ37493920-6168BA26-B5C8-4554-B123-81429B75BA95Q37594019-D3915837-2E74-45F4-BF91-8C5CC1860BE1Q37672635-2005503C-65A3-43DA-86BE-459E0E04BC64Q38011765-0FE62ECF-2D47-48F5-A257-CD589058D84AQ38090432-1F688C3B-6A2F-46CF-A244-98A17EE939D8Q38606476-E5D39302-BCA7-4594-B36C-2055548C215BQ38656581-21BA3BA0-A307-4BC2-9AEF-92D9BF8B7E5CQ39277976-A01F4A33-1073-4F43-B943-8F7812F3B441Q47096709-21BC9537-2BA9-46E9-8417-69001110DD25Q48134242-739F4F13-5E77-41D6-9947-EE3DDEA4145BQ49800452-160EB1D9-01AB-4794-B599-68F6E50E9187Q51604439-34EFC906-F13F-40D4-8751-FDC2BD0E2287Q54349937-978D4F89-0774-4605-8E51-E0E65F1FD0EB
P2860
KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
KX-01, a novel Src kinase inhi ...... ptor α positive breast cancer.
@en
KX-01, a novel Src kinase inhi ...... ptor α positive breast cancer.
@nl
type
label
KX-01, a novel Src kinase inhi ...... ptor α positive breast cancer.
@en
KX-01, a novel Src kinase inhi ...... ptor α positive breast cancer.
@nl
prefLabel
KX-01, a novel Src kinase inhi ...... ptor α positive breast cancer.
@en
KX-01, a novel Src kinase inhi ...... ptor α positive breast cancer.
@nl
P2093
P2860
P1476
KX-01, a novel Src kinase inhi ...... ptor α positive breast cancer.
@en
P2093
Brian G Rowan
David Hangauer
Latonya Carrier
Muralidharan Anbalagan
Seth Glodowski
P2860
P2888
P304
P356
10.1007/S10549-011-1513-3
P407
P577
2011-04-21T00:00:00Z